Investments
96Portfolio Exits
12Funds
6About Desjardins Capital
Desjardins Capital is the development capital fund management arm of Desjardins Group. It fuels the expansion of SMEs and cooperatives alike by providing them with the strategic and financial support needed. By investing in all regions of Quebec and in all major business sectors with strong growth potential, it has become one of the most solidly established and active development capital companies in Quebec.

Want to inform investors similar to Desjardins Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Desjardins Capital News
Mar 10, 2023
Four Canadian Health Tech stocks rated by Desjardins Things are looking up for the Healthcare Technology space, according to Desjardins Capital Markets who delivered on Thursday an update on the sector. The report says demographics, overworked healthcare systems and growing interest in private health care provision are all looking like tailwinds for stocks. Desjardins analyst Jerome Dubreuil argued that an industry-wide shortage of practitioners is part of the picture, pointing to a rash of 13 healthcare worker strikes in the United States over the past 12 months as evidence, where workers are saying they’re understaffed and overworked, leading to higher burnout rates and higher employee turnover. The result is an environment which is ripe for more investment in technology to help ease some of the burdens on healthcare systems, the analyst said. “We believe it could become more difficult for healthcare workers to address the growing burden they face unless decision-makers accept the need to invest more in technology,” Dubreuil wrote. On the Canadian side, Dubreuil noted recent moves by the Ontario government to involve private sector clinics in easing the backlog of procedures built up over the pandemic, along with a recent poll of Quebecers which suggested the population is more amenable to private sector involvement to support provincial healthcare delivery. Dubreuil said expansion of private clinics would be good for a number of companies, including WELL Health Technologies and Think Research. The analyst also noted the increase in use of telehealth services will be of benefit to companies like WELL Health and Dialogue Health Technologies. “While practitioner shortages may also affect private companies, we believe the data suggests the gap between the demand and supply of healthcare services is widening. We believe this trend, coupled with greater willingness on the part of governments in Canada to allow more private sector involvement in the healthcare sector, should benefit the healthcare technology companies we cover,” he said.
Desjardins Capital Investments
96 Investments
Desjardins Capital has made 96 investments. Their latest investment was in Puzzle Medical Devices as part of their Series A on February 2, 2023.

Desjardins Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/27/2023 | Series A | Puzzle Medical Devices | $25.03M | Yes | BDC Capital, Cordis-X, Desjardins Capital, Longview Ventures, and Undisclosed Investors | 2 |
2/14/2023 | Series A | PreVu3D | $10M | No | 4 | |
1/19/2023 | Unattributed VC | Cegerco | Yes | 1 | ||
11/22/2022 | Series B | |||||
10/21/2022 | Series A |
Date | 2/27/2023 | 2/14/2023 | 1/19/2023 | 11/22/2022 | 10/21/2022 |
---|---|---|---|---|---|
Round | Series A | Series A | Unattributed VC | Series B | Series A |
Company | Puzzle Medical Devices | PreVu3D | Cegerco | ||
Amount | $25.03M | $10M | |||
New? | Yes | No | Yes | ||
Co-Investors | BDC Capital, Cordis-X, Desjardins Capital, Longview Ventures, and Undisclosed Investors | ||||
Sources | 2 | 4 | 1 |
Desjardins Capital Portfolio Exits
12 Portfolio Exits
Desjardins Capital has 12 portfolio exits. Their latest portfolio exit was oxio on February 21, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/21/2023 | Acquired | 5 | |||
8/3/2021 | Acquired | 3 | |||
3/23/2021 | Acquired | 9 | |||
Desjardins Capital Acquisitions
2 Acquisitions
Desjardins Capital acquired 2 companies. Their latest acquisition was P.H. Tech on June 17, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/17/2022 | Management Buyout | 3 | ||||
10/11/2013 |
Date | 6/17/2022 | 10/11/2013 |
---|---|---|
Investment Stage | ||
Companies | ||
Valuation | ||
Total Funding | ||
Note | Management Buyout | |
Sources | 3 |
Desjardins Capital Fund History
6 Fund Histories
Desjardins Capital has 6 funds, including Desjardins Capital Fintech Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/10/2019 | Desjardins Capital Fintech Fund | $34M | 1 | ||
11/23/2015 | Capital regional et cooperatif Desjardins | ||||
12/31/2008 | Innovatech SEC | ||||
Capital croissance PME | |||||
Transatlantic Fund |
Closing Date | 6/10/2019 | 11/23/2015 | 12/31/2008 | ||
---|---|---|---|---|---|
Fund | Desjardins Capital Fintech Fund | Capital regional et cooperatif Desjardins | Innovatech SEC | Capital croissance PME | Transatlantic Fund |
Fund Type | |||||
Status | |||||
Amount | $34M | ||||
Sources | 1 |
Desjardins Capital Team
1 Team Member
Desjardins Capital has 1 team member, including former Chief Operating Officer, Louis L Roquet.
Name | Work History | Title | Status |
---|---|---|---|
Louis L Roquet | Chief Operating Officer | Former |
Name | Louis L Roquet |
---|---|
Work History | |
Title | Chief Operating Officer |
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.